Company Filing History:

15 out of 4,447

Eli Lilly and Company

patents

1 out of 637

Bristol-myers Company

patents

Years Active: 1989-1998

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5736544 - Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor (1998-04-07),

2. 5705519 - Method for treating 5-HT.sub.2B receptor related conditions (1998-01-06),

3. 5688807 - Method for treating 5HT.sub.2B receptor related conditions (1997-11-18),

4. 5594034 - Method of inhibiting gastric acid secretion with (1997-01-14),

5. 5594025 - Method of inhibiting gastric acid secretion with (1997-01-14),

6. 5576352 - Method of inhibiting gastric acid secretion with aryloxypropanolamines (1996-11-19),

7. 5457120 - Method of inhibiting gastric acid secretion with 4- amino-1, 3, 4, 5 (1995-10-10),

8. 5434174 - Isoxazole derivatives for the treatment of irritable bowel syndrome (1995-07-18),

9. 5387690 - Method of treating inflammatory bowel disease (1995-02-07),

10. 5340838 - Method of inhibiting gastric acid secretion with (1994-08-23),

11. 5258379 - Method of inhibiting gastric acid secretion with n-arylpiperazines (1993-11-02),

12. 5216002 - Method of treating inflammatory bowel disease (1993-06-01),

13. 5158956 - Method of inhibiting gastric acid secretion with benzodioxanes (1992-10-27),

14. 5096908 - Method of inhibiting gastric acid secretion (1992-03-17),

15. 4920102 - Method for treating gastrointestinal disorders (1990-04-24),

Title: Inventor Profile: Jaswant S Gidda

Introduction

Jaswant S Gidda, an accomplished inventor based in Carmel, Indiana, has made significant contributions to the field of medicinal chemistry. With a total of 16 patents to his name, his work primarily focuses on innovative compounds that have therapeutic applications, specifically targeting the 5-HT2B receptor.

Latest Patents

Among his latest patents, Jaswant has developed Naphthylpiperazinyl compounds that are useful for treating 5-HT2B receptor-related conditions. This invention provides methods for effectively binding to the 5-HT2B receptor in mammals using both previously known and novel compounds. Additionally, it outlines a method for treating or preventing conditions related to the 5-HT2B receptor, along with an article of manufacture related to these compounds.

Career Highlights

Jaswant S Gidda has built a robust career, working at prestigious pharmaceutical companies such as Eli Lilly and Company and Bristol-Myers Squibb. His extensive work in the industry highlights his commitment to addressing complex medical needs through targeted innovations.

Collaborations

Throughout his career, Jaswant has collaborated with notable professionals, including John M. Schaus and James E. Audia. These collaborations have likely contributed to the innovative nature of his patents, enriching his work with diverse insights and expertise.

Conclusion

In conclusion, Jaswant S Gidda stands out as a prominent inventor whose contributions to the medicinal field reflect a blend of creativity and scientific rigor. His patents focused on the 5-HT2B receptor pave the way for future advancements in treating related conditions, showcasing the potential impact of his innovations on healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com